COMMUNIQUÉS West-GlobeNewswire

Cannabis Leaf is Now Apotheca Biosciences (PCFP), Company's Products and R & D Focuses on Opioid Crisis, a National Public Health Emergency
04/09/2018
SAINT PETERSBURG, FL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations and cannabis delivery [...]
Scythian Biosciences Corp. Announces Andy DeFrancesco as a New Director
04/09/2018
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the " Company " or “ Scythian ”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) announced today that it has appointed Andrew DeFrancesco to [...]
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2019 After Market Close on September 10, 2018
04/09/2018
TUSTIN, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by [...]
NeoChord Announces Successful Completion of First Beating Heart Repair Procedures in China
04/09/2018
ST. LOUIS PARK, Minn., Sept. 04, 2018 (GLOBE NEWSWIRE) -- NeoChord, Inc. , a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve [...]
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients
04/09/2018
MIAMI, Sept. 04, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) has initiated a Phase 2 clinical trial to study the safety and efficacy of RAYALDEE ® as a new treatment for secondary hyperparathyroidism (SHPT [...]
Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome
04/09/2018
67% of Patients Achieved At Least a 50% Reduction in Convulsive Seizures Global Phase 3 Randomized, Controlled Study in LGS Currently Enrolling Patients EMERYVILLE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, [...]
MediWound to Present at 13th Annual Wells Fargo Securities Healthcare Conference
04/09/2018
YAVNE, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, [...]
AIT Therapeutics to Present Nitric Oxide Data at Two Upcoming Scientific Conferences
04/09/2018
Highlights at European Respiratory Society (ERS) to include updated data from company’s NO-BRO Pilot study of high-dose inhaled nitric oxide (NO) in infants hospitalized with acute bronchiolitis Additional pre-clinical [...]
Establishment Labs announces transition to a Direct Sales Force in the United Kingdom
04/09/2018
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics [...]
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome
04/09/2018
REDWOOD CITY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced [...]
Catalyst Biosciences Announces Publication of Marzeptacog Alfa (Activated) Phase 1 Data in The Journal of Thrombosis and Haemostasis
04/09/2018
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]
Oryzon to present at upcoming international conferences
04/09/2018
Rodman & Renshaw 20th Annual Global Investment Conference, New York, USA 19th International Conference on Alzheimer’s Drug Discovery, Jersey City, NJ, USA BIO-SPAIN-2018, Sevilla, SPAIN European Molecular Biology [...]
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
04/09/2018
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, [...]
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
04/09/2018
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the result of [...]
Surgery Partners, Inc. to Present at Wells Fargo Securities 2018 Healthcare Conference
04/09/2018
NASHVILLE, Tenn., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners”), a leading healthcare services company, today announced that Tom Cowhey, Chief Financial Officer will [...]
Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
04/09/2018
CALGARY, Alberta, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today the publication of a scientific article on the [...]
Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
04/09/2018
Dr. Jeffrey Cummings presents potential new therapy in dementia CALGARY, Alberta and SHANGHAI, Sept. 04, 2018 (GLOBE NEWSWIRE) -- As a follow up to its July 17, 2018 news release , Resverlogix Corp. (“Resverlogix” or [...]
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
04/09/2018
Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing [...]
Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine
04/09/2018
Six-month data demonstrates: A statistically superior mucosal immune response providing a first line of defense against infection; A durable serum immune response at six months compared to over 50% decline with Fluzone [...]

Pages